Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study

被引：0

作者：

Wei, H. ^{[1
]}

Zhou, X. ^{[1
]}

Yang, H. ^{[1
]}

Gong, Y-L. ^{[2
,3
]}

Wang, J. ^{[1
]}

Xu, Y. ^{[1
]}

Zhou, L. ^{[1
]}

Xue, J. ^{[1
]}

Zou, B. ^{[4
]}

Zhang, Y. ^{[1
]}

Zhu, J. ^{[1
]}

Peng, F. ^{[1
]}

Huang, M. ^{[1
]}

Lu, Y. ^{[1
]}

Liu, Y. ^{[1
]}

机构：

[1] Sichuan Univ, Dept Thorac Oncol, West China Hosp, Chengdu, Peoples R China

[2] Sichuan Univ, Dept Thorac Oncol, Ctr Canc, West China Hosp, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, Ctr Canc, State Key Lab Biotherapy, Chengdu, Peoples R China

[4] Sichuan Univ, Sch Med, West China Hosp, Dept Thorac Oncol, Chengdu, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1832

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1227P

引用

页码：S973 / S973

页数：1

共 50 条

[21] Efficacy and Safety of Chemotherapy or EGFR-TKIs as First-Line Therapy in NSCLC Patients Harboring Non-Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
Liao, Chen
Bai, Li
He, Tingting
Liang, Qingle
Hu, Defeng
Lei, Shipeng
He, Yong
Wang, Yubo
CANCER MEDICINE, 2025, 14 (01):
[22] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
Wang, Shuhang
Su, Xiaomei
Bai, Hua
Zhao, Jun
Duan, Jianchun
An, Tongtong
Zhuo, Minglei
Wang, Zhijie
Wu, Meina
Li, Zhenxiang
Zhu, Jian
Wang, Jie
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
[23] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
Shuhang Wang
Xiaomei Su
Hua Bai
Jun Zhao
Jianchun Duan
Tongtong An
Minglei Zhuo
Zhijie Wang
Meina Wu
Zhenxiang Li
Jian Zhu
Jie Wang
Journal of Hematology & Oncology, 8
[24] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study
Hu, Chunhong
Wu, Sixuan
Deng, Renfang
Wu, Yuanqiang
Pan, Yue
Shu, Long
Wu, Fang
CANCER MEDICINE, 2023, 12 (01): : 266 - 273
[25] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study
Wu, F.
Wu, S. X.
Hu, H. C.
ANNALS OF ONCOLOGY, 2018, 29
[26] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
Ma, J.
Tan, S. H.
Yin, D.
Tran, A.
Tan, D.
Ang, M.
Takano, A.
Lim, K. H. T.
Kanesvaran, R.
Jain, A.
Rajasekaran, T.
Tan, E.
Lim, D. W.
Ng, Q. S.
Tan, W.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
[27] First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis
Gomez-Randulfe, Igor
Scanlon, Lauren A.
Carter, Mathew
Moliner, Laura
Cil, Emine
Califano, Raffaele
Summers, Yvonne
Blackhall, Fiona
Lindsay, Colin R.
Lewis, Jacob
Gomes, Fabio
LUNG CANCER, 2025, 200
[28] Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
Wang, Xiaohong
Liu, Yonggang
Meng, Zhiying
Wu, Yun
Wang, Shubin
Jin, Gaowa
Qin, Yingchun
Wang, Fengyun
Wang, Jing
Zhou, Haifei
Su, Xiaoxing
Fu, Xiuhua
Wang, Xiaolan
Shi, Xiaoyu
Wen, Zhenping
Jia, Xiaoqiong
Qin, Qiong
Gao, Yongqiang
Guo, Weidong
Lu, Shun
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
[29] Real-World Study of EGFR-TKIs Combined With Radiotherapy in Patients With Brain Metastases From Non-small Cell Lung Cancer
Liu, Yi
Zhu, Yaning
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : S11 - S11
[30] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
Sheng, Zhixin
Zhang, Yanxia
MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 7

← 1 2 3 4 5 →